as 12-17-2024 4:00pm EST
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its product offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. It derives maximum revenue from United States.
Founded: | 1996 | Country: | United States |
Employees: | N/A | City: | HOLLISTER |
Market Cap: | 390.7M | IPO Year: | 2021 |
Target Price: | $5.00 | AVG Volume (30 days): | 227.3K |
Analyst Decision: | Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.73 | EPS Growth: | N/A |
52 Week Low/High: | $1.16 - $8.91 | Next Earning Date: | 11-07-2024 |
Revenue: | $36,347,000 | Revenue Growth: | -0.98% |
Revenue Growth (this year): | 3.47% | Revenue Growth (next year): | 12.07% |
TKNO Breaking Stock News: Dive into TKNO Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Associated Press Finance
a month ago
GlobeNewswire
a month ago
GuruFocus.com
a month ago
GlobeNewswire
2 months ago
Insider Monkey
2 months ago
Zacks
2 months ago
GuruFocus.com
2 months ago
The information presented on this page, "TKNO Alpha Teknova Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.